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Abstract  A  pacemaking  system  consists  of  an  impulse  generator  and  lead  or  leads  to  carry  the
electrical  impulse  to  the  patient’s  heart.  Pacemaker  and  implantable  cardioverter  deﬁbrillator
codes  were  made  to  describe  the  type  of  pacemaker  or  implantable  cardioverter  deﬁbrillator
implanted.  Indications  for  pacing  and  implantable  cardioverter  deﬁbrillator  implantation  were
given  by  the  American  College  of  Cardiologists.  Certain  pacemakers  have  magnet-operated
reed switches  incorporated;  however,  magnet  application  can  have  serious  adverse  effects;
hence,  devices  should  be  considered  programmable  unless  known  otherwise.  When  a  device
patient  undergoes  any  procedure  (with  or  without  anesthesia),  special  precautions  have  to  be
observed  including  a  focused  history/physical  examination,  interrogation  of  pacemaker  before
and  after  the  procedure,  emergency  drugs/temporary  pacing  and  deﬁbrillation,  reprogramming
of  pacemaker  and  disabling  certain  pacemaker  functions  if  required,  monitoring  of  electrolyte
and  metabolic  disturbance  and  avoiding  certain  drugs  and  equipments  that  can  interfere  with
pacemaker  function.  If  unanticipated  device  interactions  are  found,  consider  discontinuation  of
the  procedure  until  the  source  of  interference  can  be  eliminated  or  managed  and  all  corrective
measures  should  be  taken  to  ensure  proper  pacemaker  function  should  be  done.  Post  procedure,
the  cardiac  rate  and  rhythm  should  be  monitored  continuously  and  emergency  drugs  and  equip-
ments  should  be  kept  ready  and  consultation  with  a  cardiologist  or  a  pacemaker--implantable
cardioverter deﬁbrillator  service  may  be  necessary.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroductionBattery-operated  pacing  devices  were  introduced  by  C.W.
Lillehei and  Earl  Bakken  in  1958.1 The  natural  progression
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http://dx.doi.org/10.1016/j.bjane.2013.02.005f  pacemaker  (PM)  developments  led  to  invention  of  the
mplantable cardioverter  deﬁbrillator  (ICD)  around  1980  by
ichael Morchower.1
A  pacemaking  system  consists  of  an  impulse  generator
nd lead  or  leads  to  carry  the  electrical  impulse  to  the
atient’s heart.  Leads  can  be  unipolar,  bipolar  or  multipo-
ar. Generators  with  bipolar  leads  can  be  programmed  to  the
nipolar mode  for  pacing,  sensing,  or  both.1
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Table  1  North  American  Society  of  Pacing  and  Electrophysiology  (NASPE)/British  Pacing  and  Electrophysiology  Group  (BPEG)
(2002)  Generic  Pacemaker  Code  (NBG).2
Position  I:  pacing
chamber(s)
Position II:  sensing
chamber(s)
Position III:  response(s)
to sensing
Position  IV:
programmability
Position V:
multisite  pacing
O  =  none  O  =  none  O  =  none  O  =  none  O  =  none
A =  atrium  A  =  atrium  I  =  inhibited  R  =  rate
modulation
A =  atrium
V =  ventricle V  =  ventricle  T  =  triggered  V  =  ventricle
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8D =  dual  (A  +  V) D =  dual  (A  +  V) D =  dual  (T
acemaker  codes
able  1  shows  the  pacemaker  codes  given  by  the  North  Amer-
can Society  of  Pacing  and  Electrophysiology  (NASPE)/British
acing and  Electrophysiology  Group  (BPEG)  (2002)  Generic
acemaker Code  (NBG).2
Dual:  Provides  atrioventricular  (AV)  synchrony,  where
trial pacing  will  take  place  in  the  ‘‘inhibited’’  mode  and  the
acing device  will  ensure  that  a  ventricular  event  follows.1
Inhibited:  The  appropriate  chamber  is  paced  unless
ntrinsic electrical  activity  is  detected  during  the  pacing
nterval.1
Triggered:  The  pacing  device  will  emit  a  pulse  only  in
esponse to  a  sensed  event.1
ndications  for  pacemaker  implantation3
.  Bradycardia  due  to  Sinus  Node  Dysfunction  (SND)  and
Atrioventricular  Node  Dysfunction  (AND).
-  SND:  Persistent  sinus  bradycardia  and  chronotropic
incompetence  without  identiﬁable  causes,  symp-
tomatic  bradycardia.
-  Acquired  atrioventricular  (AV)  block  in  adults:
- Third-degree  and  advanced  second-degree  AV  block  at
any  anatomic  level  associated  with:
◦ Bradycardia  with  symptoms/ventricular  arrhythmias
presumed  to  be  due  to  AV  block.
◦ Other  medical  conditions  that  require  drug  therapy
that  results  in  symptomatic  bradycardia.
◦ Symptom-free  patients  in  sinus  rhythm,  with  docu-
mented  periods  of  asystole  greater  than  or  equal  to
3  s,  an  escape  rate  <40  bpm  or  an  escape  rhythm  that
is  below  the  AV  node.
◦  Awake,  symptom-free  patients  with  AF  and  brady-
cardia  with  ≥1  pauses  of  at  least  ≥5  s.
◦  After  catheter  ablation  of  the  AV  junction  associated
with  postoperative  AV  block  that  is  not  expected  to
resolve  after  cardiac  surgery.
◦ Associated  with  neuromuscular  diseases  with  AV
block.
-  Second-degree  AV  block  with  associated  symptomatic
bradycardia  regardless  of  type  or  site  of  block.
- Asymptomatic  persistent  third-degree  AV  block  at  any
anatomic  site  with  average  awake  ventricular  rates  of
40  bpm  or  faster  if  cardiomegaly  or  LV  dysfunction  is
present  or  if  the  site  of  block  is  below  the  AV  node.
- Second-  or  third-degree  AV  block  during  exercise  in  the
absence  of  myocardial  ischemia.D =  dual  (A  +  V)
. Chronic  bifascicular  block:  Bifascicular  block  refers  to
ECG  evidence  of  impaired  conduction  below  the  AV  node
in  the  right  and  left  bundles.
- Advanced  second-degree  AV  block  or  intermittent
third-degree  AV  block.
-  Type  II  second-degree  AV  block.
- Alternating  bundle-branch  block.
.  Pacing  for  atrioventricular  block  associated  with  acute
myocardial  infarction
- Persistent  second-degree  AV  block  after  ST-segment
elevation  MI.
-  Transient  advanced  second-  or  third-degree  infranodal
AV  block  and  associated  bundle-branch  block.
- Persistent  and  symptomatic  second-  or  third-degree  AV
block.
.  Hypersensitive  carotid  sinus  syndrome  and  neurocardio-
genic syncope.
- Recurrent  syncope  caused  by  spontaneously  occurring
carotid  sinus  stimulation  and  carotid  sinus  pressure
that  induces  ventricular  asystole  of  more  than  3  s.
.  After  cardiac  transplantation.
- Persistent  inappropriate  or  symptomatic  bradycardia
not  expected  to  resolve.
.  Prevention  and  termination  of  arrhythmias  by  pacing.
-  Symptomatic  recurrent  SVT  that  is  reproducibly  termi-
nated  by  pacing  when  catheter  ablation  and/or  drugs
fail  to  control  the  arrhythmia  or  produce  intolerable
side  effects.
-  Sustained  pause-dependent  VT,  with  or  without  QT  pro-
longation.
.  Hypertrophic  cardiomyopathy.
.  Children,  adolescents,  and  patients  with  congenital
heart disease.
- Advanced  second/third-degree  AV  block  associated
with  symptomatic  bradycardia,  ventricular  dysfunc-
tion,  or  low  cardiac  output.
-  SND  with  correlation  of  symptoms  during  age-
inappropriate  bradycardia.  (The  deﬁnition  of  bradycar-
dia  varies  with  the  patient’s  age  and  expected  heart
rate.)
-  Postoperative  advanced  second-  or  third-degree  AV
block  that  is  not  expected  to  resolve  or  that  persists
at  least  7  days  after  cardiac  surgery.
- Congenital  third-degree  AV  block  with  a  wide  QRS
escape  rhythm,  complex  ventricular  ectopy,  or  ventric-
ular  dysfunction.
-  Congenital  third-degree  AV  block  in  the  infant  with  a
ventricular  rate  less  than  55  bpm  or  with  congenital
heart  disease  and  a  ventricular  rate  less  than  70  bpm.
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Indications  for  implantable  cardioverter
deﬁbrillators implantation
-  Survivors  of  cardiac  arrest  due  to  VF/hemodynamically
unstable sustained  VT.
- Structural  heart  disease  and  spontaneous  sustained  VT,
whether  hemodynamically  stable  or  unstable.
- LVEF  (Left  Ventricular  Ejection  Fraction)  ≤  35%  due  to  prior
MI  (NYHA  functional  Class  II/III)  or  LVEF  ≤  30%  due  to  prior
MI  (NYHA  functional  Class  I).
- Nonischemic  dilated  cardiomyopathy  having  an  LVEF  ≤  35%
(NYHA  functional  Class  II/III).
- Nonsustained  VT  due  to  prior  MI,  LVEF  ≤  40%.
Indications  for  implantable  cardioverter
deﬁbrillators implantation  in  pediatric  patients  and
patients with  congenital  heart  disease
-  Survivor  of  cardiac  arrest.
-  Symptomatic  sustained  VT.
Complications: Complications  can  be  due  to  the  pres-
ence of  the  pacing  system  as  a  foreign  body  (mechanical
complications), apparent  or  real  pacing  system  malfunc-
tion, acute  complications  related  to  the  procedure  itself:
hemothorax, pneumothorax,  subclavian  artery  puncture  and
myocardial perforation.4
1.  Infection:  incidence  is  0.8--5.7%4 Staphylococcus  aureus
(early  infections)  and  S.  epidermidis  (late  infections)  are
the  most  common  organisms  involved.4
-  Pacemaker  pocket  infection:  Routine  use  of  anti-
staphylococcal  antibiotic  prophylaxis  at  the  time  of
implantation  or  generator  change  has  been  shown
to  have  consistent  beneﬁt  in  a  meta-analysis  of
seven  randomized  controlled  trials,  in  2023  patients,
in  decreasing  the  rates  of  short-term  pocket  infec-
tion,  skin  erosion,  or  septicemia.5 Therefore  routine
prophylaxis  with  antistaphylococcal  antibiotics  is
recommended.4
-  Endocarditis:  Complete  eradication  of  the  infection
usually  involves  removal  of  the  entire  pacing  system.4
2.  Thrombosis:  usually  subclinical
- Embolism:  Pulmonary  (incidence  0.6--3.5%4)  and  sys-
temic  embolization.  Patients  implanted  with  a  VVI(R)
pacing  system  have  a  higher  incidence  of  paroxysmal
and  chronic  atrial  ﬁbrillation,  which  predisposes  to
embolic  events.4
3.  Pacing  problems
Failure to  capture:  The  occurrence  of  the  stimulus  out-
put,  which,  when  delivered  outside  the  refractory  period
of  atrial  or  ventricular  tissue,  is  not  followed  by  a P
wave  or  QRS  complex.  This  could  be  due  to  elevation
of  stimulation  threshold,  which  in  turn  could  be  due  to
metabolic  disturbances,  drugs  (mostly  anti-arrythmics),
acute myocardial  infarction,  pacing  lead  defects  (frac-
tures,  insulation  break),  lead  maturation,  dislodgement
or perforation,  inappropriately  low  programmed  output,
battery  end  of  life.4
-
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Failure  of  output:  This  is  manifested  on  the  surface
electrocardiogram as  an  absence  of  pacing  artifacts.  This
can  be  due  to  battery  depletion  or  component  failure4
.  Sensing  problems4:
- Oversensing  of  unwanted  signals:  A  pause  in  paced
rhythm  (AAI/VVI  modes)  or,  if  the  oversensed  atrial
event  causes  triggered  pacing  in  the  ventricle,  an
earlier  than  expected  paced  ventricular  event.  Under-
sensing  of  the  intrinsic  intracardiac  signal.
.  Rapid  paced  ventricular  rates4:
- Atrial  tachyarrhythmias:  Sinus  tachycardia,  atrial
tachycardia,  atrial  ﬂutter  and  ventricular  pacing  can
resemble  an  ‘‘electronic  AV  block,’’  and  cardiac  output
can  suddenly  decrease.
-  Pacemaker-mediated  tachycardia  (PMT).
acemaker  magnets
agnet-operated  reed  switches  within  pacemakers  were
riginally incorporated  to  produce  pacemaker  behavior
hat would  demonstrate  remaining  battery  life  and  some-
imes pacing  thresholds  and  can  be  used  to  protect  the
acemaker-dependent patient  during  diathermy,  electro-
autery or  other  sources  of  pulsed  EMI  (electro  magnetic
nterference).6 Magnets  can  be  applied  over  the  pacemaker
o avoid  inhibition  by  such  pulsed  interference.6 In  modern
acemakers, the  switch  to  asynchronous  pacing  is  coupled
o the  next  cardiac  event  to  avoid  competition  at  the  out-
et. Placement  of  a  magnet  over  a  generator  might  produce
o change  in  pacing  because  not  all  pacemakers  switch  to  a
ontinuous asynchronous  mode  when  a  magnet  is  applied.1
n  some  devices  magnet  behavior  can  be  altered  by  program-
ing, whereas  in  others,  magnet  behavior  can  be  completely
liminated by  programming.  For  all  generators,  calling  the
anufacturer remains  the  most  reliable  method  of  deter-
ining magnet  response  and  using  this  response  to  predict
emaining battery  life.1 However,  the  Task  Force  cautions
gainst the  use  of  the  magnet  over  an  ICD.6
As  battery  voltage  falls,  the  magnet  response  can  be  used
o detect  the  following:1
 IFI  (intensiﬁed  follow-up  required)  --  the  device  must  be
checked  frequently  (approximately  every  4  weeks  for  most
models).
 ERI  (elective  replacement  indicator)  --  the  device  is  near-
ing  the  end  of  its  useful  life  and  should  be  electively
replaced.
 EOL  (end  of  life)  --  the  device  has  insufﬁcient  battery
power  remaining  and  should  be  replaced  immediately.
Problems  with  magnet  application:
 Switching  to  asynchronous  pacing  may  trigger  ventricular
asynchrony  in  patients  with  myocardial  ischemia,  hypoxia,
and  electrolyte  imbalance.5
 Constant  magnet  application  over  the  pacemaker  may
alter  the  programming  and  can  also  cause  continuous  or
transient  loss  of  pacing.7
 Variability  of  response  between  devices.8
 Occasionally,  PMT  can  ensue  on  removal  of  the  magnet
from  a  dual-chamber  PM.1
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Table  2  Commonly  used  pacing  modes.4
Position  of  letter  Description
I
Chamber
paced
II
Chamber
sensed
III
Mode  of
response
IV
Rate
adaptation
A  O  O  Asynchronous  (ﬁxed  rate)  atrial  pacing
A  A  T  Triggered  atrial  pacing.  Output  pulse  is  delivered  (and
sensed  by  the  atrial  electrode)  at  the  time  of  sensing,  or  at
the programmed  escape  interval  (rarely  used)
A  A  I  Demand  atrial  pacing;  output  inhibited  by  sensed  atrial
activity
A A  I  R  Demand  atrial  pacing;  output  inhibited  by  sensed  atrial
activity;  paced  rates  increase  and  decrease  in  response  to
sensor input
V O  O  Asynchronous  (ﬁxed  rate)  ventricular  pacing
V  V  T  Triggered  ventricular  pacing.  Output  is  delivered  (and
sensed  by  the  ventricular  electrode)  at  the  time  of  sensing
or at  the  programmed  escape  interval  (rarely  used)
V  V  I  Demand  ventricular  pacing;  output  inhibited  by  sensed
ventricular  activity
V V  I  R  Demand  ventricular  pacing;  output  inhibited  by  sensed
ventricular  activity;  paced  rates  decrease  and  increase  in
response  to  sensor  input.
V D  D  Paces  ventricle;  senses  in  both  atrium  and  ventricle  and
paces  ventricle  after  the  programmed  atrioventricular
interval.
D  D  I  Demand  atrial  and  ventricular  pacing;  tracking  of  atrial
rhythm  does  not  occur
D D  I  R  Demand  atrial  and  ventricular  pacing;  paced  rates  increase
and  decrease  in  response  to  sensor  input;  tracking  of  atrial
rhythm  does  not  occur
D D  D  Paces  and  senses  in  both  atrium  and  ventricle;  paced
activity  up  to  programmed  upper  rate  limit
D  D  D  R  Paces  and  senses  in  both  atrium  and  ventricle;  paces  up  to
the programmed  upper  rate  limit;  paced  rates  increase  and
m
c
I
I
a
m
e
d
l
a
h
c
E
o
T
f
t
t
I
f
I
r
i
I
V
a
P
MThus,  in  nonprogrammable  pacemaker,  the  use  of  magnet
ay be  safe.  However,  the  most  current  devices  should  be
onsidered programmable  unless  known  otherwise.9
Table  2 shows  the  commonly  used  pacing  modes.4
mplantable cardioverter deﬁbrillator (ICD)
CD  consists  of  pulse  generator,  pacing  or  sensing  electrodes,
nd deﬁbrillation  coils.  Its  function  is  similar  to  a  pace-
aker and  hence  susceptible  to  the  same  complications  and
mergencies as  a  pacemaker.  In  addition,  an  ICD  senses  and
etects ventricular  tachycardia  (VT)  and  ventricular  ﬁbril-
ation (VF)  and  delivers  therapy  in  the  form  of  overdrive
ntitachycardia pacing  (ATP),  low-energy  cardioversion,  and
igh-energy deﬁbrillation.  Table  3  shows  a  four-place  ICD
ode,2 given  by  the  North  American  Society  of  Pacing  and
lectrophysiology (NASPE)/British  Pacing  and  Electrophysi-
logy Group  (BPEG)  (2002)  Generic  Deﬁbrillator  Code  (NBD).
he fourth  position  of  the  code  is  the  three/ﬁve-letter  code
or the  pacemaker  capability  of  the  device.2
I
w
o
edecrease  in  response  to  sensor  input
ICD  shock  can  lead  to  transient  post-shock  loss  of  cap-
ure and  sensing  in  the  pacemaker  because  of  exposure  of
he myocardium  to  high  current  density.  In  patients  with
CDs and  separate  pacemakers,  the  pacing  stimulation  arti-
act (PSA)  can  cause  over-sensing  or  under-sensing  in  the
CD lead  resulting  in  inappropriate  ICD  therapy.  Hence,  it  is
ecommended that  pacing  at  the  chronic  pacing  amplitude
n sinus  rhythm  should  cause  a  PSA  amplitude  <1  mV  on  the
CD rate  sense  lead  to  ensure  appropriate  ICD  sensing  during
F.4,10
It  is  imperative  that  ICD  patients  undergo  routine  evalu-
tion (every  three  months  and  after  each  exposure  to  EMI).4
acemakers and special circumstances:
agnetic  resonance  imaging  (MRI)t  is  estimated  that  up  to  75%  of  pacemaker  patients
ill have  a  medical  need  for  an  MRI  over  the  lifetime
f their  device.11 Scanning  device  patients  is  now  consid-
red a relative  contraindication  (vs  absolute).12,13 Device
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Table  3  NASPE/BPG  Generic  Deﬁbrillator  Code  (NBD).2
Position  I  shock
chambers
Position  II  antitachycardia
pacing chambers
Position  III  tachycardia
detection
Position  IV  antibradycardia
pacing chambers
O  =  none  O  =  none  E  =  electrogram  O  =  none
A =  atrium  A  =  atrium  H  =  hemodynamic  monitors  A  =  atrium
V =  ventricle  V  =  ventricle  V  =  ventricle
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aD =  dual  (A  +  V)  D  =  dual  (A  +  V)  
manufacturers  have  made  changes  in  devices  to  make
them more  compatible  with  MRI  (less  use  of  ferromagnetic
material in  battery  construction).14 MRI  affects  pacemaker
function in  various  ways:
Static  magnetic  ﬁeld  --  can  result  in  actual  physical  move-
ment  of  the  pulse  generator’s  internal  components.4
Modulated  radio  frequency  (RF)  ﬁeld  --  can  result  in
induced  voltage  across  the  pacemaker  electrodes  that  may
stimulate  myocardial  tissue,  leading  to  rates  equal  to  the
MRI  pulsing  rates  (cycle  lengths  of  200--1000  ms),15 heat-
ing  of  cardiac  tissue  adjacent  to  lead  electrodes  causing
thermal  injury  to  myocardium  and  endocardium.16
Gradient  magnetic  ﬁeld  --  can  cause  over-sensing  or
under-sensing,  and  can  induce  negligible  heating  effect.17
While  doing  MRI  --  magnet  response,  rate  response,  noise
response, ventricular  sense  response,  premature  ventricular
contraction response,  conducted  atrial  ﬁbrillation  response,
and tachyarrhythmia  functions  --  should  be  disabled.4
Pacemaker-dependent  patients  should  be  programmed  to
VOO mode  and  non-pacemaker-dependent  patients  can  be
programmed to  the  VVI  or  DDI  mode.18
Guideline  recommendations  with  regard  to  performing
MRIs in  nonpacemaker  dependent  patients.12,13,19--21
i.  Decision  should  be  weighed  principally  on  risk-beneﬁt
ratio  and  the  urgency  of  the  clinical  indication  for  MRI.
ii. Obtain  a  written  and  verbal  informed  consent.
iii. Before  taking  the  patient  for  MRI,  pacemaker  functions
should be  pretested.
iv.  A  cardiologist  should  decide  whether  it  is  necessary  to
program  the  pacemaker  prior  to  the  MRI.
v. Advanced  Cardiac  Life  Support  (ACLS)  personnel  must
be  in  attendance  for  the  entire  MRI  examination  and  a
crash  cart,  and  deﬁbrillator  must  be  available  onsite.
vi. The  patient  should  be  monitored  and  visual/voice
contact with  the  patient  should  be  maintained  contin-
uously  during  the  MRI.
vii.  After  the  MRI  examination,  a  cardiolo-
gist/electrophysiologist  should  interrogate  the
pacemaker to  conﬁrm  that  the  function  is  consistent
with the  pre-examination  state.
Exposure  to  MRI  has  similar  effects  on  an  ICD  as  those
described for  a  cardiac  pacemaker,  since  some  of  the  basic
components are  comparable.4 ICDs  may  falsely  detect  the
Magnetic Resonance  Radio  Frequency  ﬁeld  as  VF,  charge
capacitors, and  deliver  ATP,  cardioversion,  or  deﬁbrilla-
tion therapies.16 Devices  may  not  be  able  to  deliver  ICDD  =  dual  (A  +  V)
herapy  in  the  static  magnetic  ﬁeld  and  the  ICD  transformer
ill be  magnetically  saturated  and  may  not  have  the  volt-
ge necessary  to  charge  the  capacitor,  and  hence  can  lead  to
ermanent device  failure.  Magnetic  ﬁelds  may  also  prevent
etection of  VT  or  VF.
lectrocautery  and  anesthesia
lectrocautery  is  the  most  common  exogenous  source  of  EMI6
hat  can  interact  with  pacemakers,  resulting  in  pulse  gener-
tor inhibition,  electrical  burns  at  the  myocardial--electrode
nterface, atrial  or  ventricular  tachycardia  and  ﬁbrillation,
ulse generator  component  failure,  loss  of  or  change  in
utput, reprogramming  of  rate  or  mode  of  function  and  run-
way  pacing.22--24 The  EMI  generated  by  electrocautery  that
ay affect  the  device  is  related  to  the  distance  and  ori-
ntation of  the  current  to  the  patient’s  device  and  leads.
 prospective  study  has  shown  that  unipolar  devices  are
ar more  susceptible  than  bipolar  devices  to  electrocautery
nference.24 In  bipolar  coagulation  cautery,  the  current  ﬂow
s localized  between  the  two  poles  of  the  instrument,  and
herefore poses  minimal  problems.  However,  in  unipolar
lectrocautery devices,  the  electrical  current  ﬂow  is  not
estricted to  the  tissue  interposed  between  two  electrodes
nd spreads  throughout  the  body.4 The  vector  of  the  dipole
or the  electrocautery  device  with  respect  to  that  of  the
acemaker should  not  intersect  with  each  other.25 Hence,
he EMI  generated  by  electrocautery  that  may  affect  the
evice is  related  to  the  distance  and  orientation  of  the  cur-
ent to  the  patient’s  device  and  leads.26 Special  precautions
re26,27:
1.  Using  a  bipolar  electrocautery  system/ultrasonic  (har-
monic)  scalpel,  if  possible.6
2.  If  only  unipolar  electrocautery  is  available,  then  the
indifferent  electrode  should  be  placed  as  far  from  the
pacemaker  leads  as  possible.4
3.  Assure  that  the  cautery  tool  and  current  return  pad  are
positioned  so  that  the  current  pathway  does  not  pass
through  or  near  the  CRMD  (Cardiac  Rhythm  Management
Devices)  pulse  generator  and  leads.6
4.  Using  short,  intermittent,  and  irregular  bursts  at  the
lowest  feasible  energy  levels5 to  minimize  the  hemody-
namic effects  of  pacemaker  inhibition.4
5.  A  magnet  should  not  be  applied  prophylactically,
because there  is  no  uniform  pulse  generator  response
to this  maneuver.4
6.  Electrocautery  can  cause  electromagnetic  noise  on  the
ICD  sensing  lead  that  is  detected  as  VF  and  can  lead  to
inappropriate  shock.4
21
1
1
D
S
s
t
E
E
o
t
r
m
s
a
m
(
p
E
n
u
d
d
t
a
a
i
C
s
t
O
E
e
t
t
a
i
ﬁ
c
r
t
s
R
T
r
g
c
d
R
T
a
p
e
f
f
e
b
b
e
r
e
b
s
r
t
d
s
c
h
p
O
e
E
w
e
a
t
b
v
i
o
a
t
w
i
i
c
C
T
p10  
7.  Therefore  the  detection  and  therapy  can  be  pro-
grammed to  ‘‘off’’  during  surgery  and  turn  it  ‘‘on’’
postoperatively; external  deﬁbrillators  are  used  for
intra-operative  VT/VF.4
8.  The  availability  of  programming  equipment  and  trained
personnel  is  essential.
9.  Alternative  temporary  pacing  should  be  ready  in  the
OT.26
0.  Drugs  such  as  isoproterenol  and  atropine  should  be
available.8
1.  Careful  monitoring  of  the  patient.
2. The  device  should  always  be  checked  after  operation.
iathermy
hort-wave  diathermy  should  be  avoided  near  the  generator
ite. Potential  problems  include  overheating  of  the  genera-
or circuitry  and  damage  to  electronic  components.6
lectroconvulsive  therapy  (ECT)
CT  is  relatively  safe  for  patients  with  pacemakers,  because
f the  localized  application  of  the  electrical  stimulus
o the  head,  hence  a  low  probability  for  the  occur-
ence of  problems.4 Sometimes  the  seizure  may  generate
yopotentials which  may  inhibit  the  pacemaker,  and  tran-
ient  electrocardiographic  changes  (e.g.,  increased  P-wave
mplitude, altered  QRS  shape,  T-wave  and  ST-T  abnor-
alities) may  occur  and  additional  cardiac  complications
e.g., arrhythmia  or  ischemia)  may  occur  in  patients  with
re-existing cardiac  disease.  The  Task  Force  believes  that
CT may  be  administered  to  CRMD  patients  without  sig-
iﬁcant damage  to  a  disabled  CRMD.  All  CRMDs  should
ndergo a  comprehensive  interrogation  before  the  proce-
ure(s). ICD  functions  should  be  disabled  for  shock  therapy
uring ECT.6 Therefore,  monitoring  and  standard  resusci-
ation equipment,  and  a  trained  programmer,  should  be
vailable28 and  pacemakers  can  be  changed  to  nonsensing
synchronous mode  (ﬁxed  mode),29 to  avoid  myopotential
nhibition of  the  device  in  pacemaker-dependent  patients.6
RMD-dependent  patients  may  require  a  temporary  pacing
ystem to  preserve  cardiac  rate  and  rhythm  during  shock
herapy.
ther  electrical  stimulating  techniques
lectrical  stimulating  techniques  such  as  transcutaneous
lectrical nerve  stimulation  (TENS)  consists  of  several  elec-
rodes placed  on  the  skin  and  connected  to  a  pulse  generator
hat applies  20  s  rectangular  pulses  of  1--200  V  and  0--60  mA
t a  frequency  of  20--110  Hz.  This  repeated  frequency  is  sim-
lar to  the  normal  range  of  heart  rates,  so  it  can  create  a  far
eld potential  that  may  inhibit  a  cardiac  pacemaker.6 TENS
an be  used  safely  in  patients  with  pacemakers  and  deﬁb-
illators with  close  monitoring  and  use  in  close  proximity  to
he device  is  not  advised.30
PMT  has  been  reported  to  be  induced  by  intraoperative
omatosensory  evoked  potential  stimulation.31
m
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adiofrequency  ablation  (RFA)
he  radiofrequency  current  path  (electrode  tip  to  current
eturn pad)  should  be  kept  as  far  away  from  the  pulse
enerator and  lead  system  as  possible  and  to  avoid  direct
ontact between  the  ablation  catheter  and  the  CRMD  (Car-
iac Rhythm  Management  Devices).6
adiation  therapy
he  high-energy  ionizing  radiation  used  in  radiation  ther-
py can  cause  signiﬁcant  damage  to  the  semiconductors  of
acemakers, even  at  very  small  doses.31 Generally,  doses  in
xcess of  5000  rads  are  required  to  cause  pacemaker  mal-
unction but  as  little  as  1000  rads  may  induce  pacemaker
ailure or  cause  runaway  pacemaker.8 Pulse  generator  recov-
ry may  occur  long  after  the  end  of  the  radiation  treatment,
ut it  is  mostly  incomplete,  and  the  pacemaker  cannot
e used  reliably  thereafter.32,33 Thus,  in  pulse  generators
xposed to  radiation,  transient  loss  of  function  should  be
egarded as  a precursor  of  permanent  damage.  Hence  it  is
ssential to  follow  guidelines  for  ensuring  the  lowest  possi-
le radiation  dose  to  the  pacemaker34 and  careful  follow-up
hould be  performed  during  and  after  completion  of  the
adiation therapy.  The  Task  Force  believes  that  radiation
herapy can  be  safely  performed  for  CRMD  patients.  The
evice must  be  outside  the  ﬁeld  of  radiation.6 Therefore,
ome pulse  generators  will  require  surgical  relocation  before
ommencing radiation.
The low-energy  X-rays  used  for  diagnostic  radiology
ave not  been  reported  to  have  any  adverse  effect  in
acemakers.4
ther  minor  surgical  procedures  (lithotripsy,
ndoscopic electrocautery)
xtracorporeal  shock  wave  lithotripsy  (ESWL)  is  associated
ith electromagnetic  and  mechanical  forces  that  may  inﬂu-
nce  pacing  system  function.35 Pulse  generators  employing
 piezoelectric  crystal  sensor  seem  to  be  the  most  suscep-
ible to  failure,36 and  therefore  the  sensor  mode  should
e programmed  ‘‘off’’  during  lithotripsy  as  this  will  pre-
ent an  unwanted  increase  in  paced  heart  rate  and  shatter
njury to  the  piezoelectric  element.  Therefore,  focal  point
f the  lithotriptor  should  be  kept  at  least  six  inches  (15  cm)
way from  the  pacemaker,37 and  disabling  atrial  pacing  if
he lithotripsy  system  triggers  on  the  R  wave.7 Low  shock
aves (<16  kV)  should  be  used  initially  followed  by  a  gradual
ncrease in  the  level  of  energy.38 Endoscopic  electrocautery
s generally  safe  in  patients  with  pacemakers,  although
omplications have  been  reported.39
ardiopulmonary  resuscitation
he  standard  resuscitation  protocols  should  be  followed  in
atients with  permanent  pacemakers,  and  normal  pace-
aker function  should  be  established  after  the  resuscitation
rocedure is  completed.4 Myocardial  stimulation  threshold
s markedly  increased  during  cardiopulmonary  resuscitation4
nd  even  though  most  sensing  and  pacing  problems  are
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transient,  a  thorough  evaluation  of  the  pacing  system,
including interrogation  and  programming  functions,  should
be  made  after  the  resuscitation  procedure.4
Direct  current  cardioversion  and  deﬁbrillation
The  cardioverter-deﬁbrillator  can  cause  capacitive  coupling
with the  endocardial  lead,  causing  direct  discharge  at  the
electrode--endocardium interface,4,40 thus  leading  to  tran-
sient/permanent failure  to  sense  and  capture  even  in  the
absence of  apparent  damage  to  the  pulse  generator  itself.41
Damaged  circuitry,42,43 changes  in  programmed  mode  of
function, complete  pacemaker  failure  and  microdislodge-
ment of  the  lead  can  also  occur.4,44 Deﬁbrillation  with
internal cardiac  paddles  requires  less  energy  but  may  also
interfere with  pacemaker  function.45,46 Modern  pacemakers
are equipped  with  protection  mechanisms  against  damage
from DC  shock,  most  common  of  which  is  the  Zener  diode,47
which  directs  a  surge  in  current  toward  the  electrode,  pro-
tecting the  pacemaker  circuitry  but  delivering  this  energy  to
the endocardium.  The  general  precautions  for  DC  cardiover-
sion and  deﬁbrillation  in  patients  with  pacemakers  attempt
to minimize  the  current  delivered  to  the  pacemaker  system
by using  the  minimal  effective  energy  setting4,6 and  placing
the deﬁbrillator  paddles  at  least  10  cm  away  from  the  pulse
generator, ensuring  that  the  paddles  are  placed  perpendicu-
lar to  the  dipole  of  the  pacing  system.  A  thorough  evaluation
of the  pacing  system  should  be  performed4 and  if  loss
of capture  occurs,  and  then  immediate  reprogramming  or
temporary pacing  should  be  done  with  increased  generator
output.48,49 The  Task  Force  believes  that  before  attempting
emergency deﬁbrillation  or  cardioversion  of  a  patient  with
an ICD  and  magnet-disabled  therapies,  all  sources  of  EMI
should be  terminated,  and  the  magnet  should  be  removed
to re-enable  antitachycardia  therapies  and  then  consider
reenabling therapies  through  programming.6
Bioelectrical  impedance  analysis  (BIA)
BIA  employs  bioimpedence  spectroscopy  techniques  which
measures at  50  frequencies  over  a  range  from  5  to  1000  kHz
to determine  the  electrical  resistances  of  TBW  and  ECW
to provide  an  estimate  of  body  cell  mass  and  to  describe
ﬂuid shifts  and  ﬂuid  balance,50 but  not  recommended  for
participants with  a  pacemaker.51
Bioimpedance  tomography/thoracic  electrical
bioimpedance (TEB)
This  uses  pulsating  and  polarized  electric  current  at  a  fre-
quency not  higher  than  10  Hz,  and  provides  information  on
the impedance  of  the  extracellular  environment.52 However
their use  is  not  recommended  for  patients  with  minute  ven-
tilation (MV)  sensor  function  pacemakers,  since  sensors  are
very sensitive  to  stray  electromagnetic  interference,  and
patients have  been  inappropriately  treated  for  pacemaker-
driven tachycardias  as  a  result.  Therefore,  rate  modulation
should be  programmed  to  ‘‘OFF’’  in  the  peri-operative
period to  prevent  confusion  between  an  intrinsic  tachycar-
dia vs  a  pacemaker-induced.1,14
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etabolic  abnormalities
lectrolyte  and  metabolic  abnormalities  (hyperkalemia,
yperglycemia, alkalemia,  acidosis,  hypoxemia,  hyper-
apnia and  hypothyroidism)  increase  the  pacing
hreshold, causing  failure  to  capture.53 Therefore,
ggressive correction  of  the  underlying  disturbance  is
ssential.
ystolic  heart  failure
he  presence  of  a  permanent  pacemaker  has  been  reported
o be  an  independent  predictor  of  poor  outcome  in  patients
ith heart  failure,4,54 and  hence  evidence  of  pacemaker
alfunction and  must  be  carefully  evaluated.
re anesthetic consideration
reoperative  evaluation  of  a  patient  with  pacemaker  under-
oing noncardiac  surgery  includes  general  evaluation  of  the
atient and  the  pacemaker.
The  consensus  of  the  Task  Force6 is  that  a  focused  pre-
perative evaluation  should  include:
. Establishing  whether  a  patient  has  a  CRMD  --  a  focused
history and  physical  examination
.  Deﬁning  the  type  of  device  --  obtaining  the  manufac-
turer’s identiﬁcation  card  from  the  patient  or  other
source,  chest  X-ray  (if  no  other  data  are  available)
c. Determining  whether  a  patient  is  CRMD  dependent  for
pacemaking  function.
.  Determining  CRMD  function  by  a  comprehensive  evalu-
ation  of  the  device,  consultation  with  a cardiologist  or
a  CRMD  service,  contacting  the  manufacturer  for  peri-
operative  recommendations.
ACC guidelines  suggest  that  cardiac  testing  (stress  tests,
chocardiograms) be  dictated  by  the  patient’s  underlying
isease, medications,  symptomatology,  interval  from  last
esting,  and  planned  intervention.55
No  special  laboratory  tests  or  radiographs  are  needed  for
atients with  a conventional  PM.  However,  a  patient  with
 BiV  PM  or  ICD  might  need  a  chest  ﬁlm  to  document  the
osition of  the  coronary  sinus  lead,  especially  if  central  line
lacement is  planned.  Most  current  CRMDs  have  an  X-ray
ode that  can  be  used  to  identify  the  manufacturer  of  the
evice.6
The  generator  should  be  identiﬁed,  and  the  location  of
he pulse  generator  should  be  noted.  Generally,  genera-
or for  the  epicardial  electrodes  is  kept  in  the  abdomen
nd over  one  of  the  pectoris  muscles  for  the  endocardial
lectrodes.6 If  interrogation  is  not  an  option,  one  can  slow
he intrinsic  heart  rate  to  a  rate  below  that  of  the  pacemaker
y carotid  massage  or  a  Vasalva  maneuver.1,56 Any  device
ear its  elective  replacement  period  should  be  considered
or replacement.  Ten  percent  decrease  in  the  rate  from
he time  of  implantation  indicates  power  source  depletion.8he  patient’s  underlying  rate  and  rhythm  should  be  deter-
ined (which  then  determines  the  need  for  backup/external
acing support).  All  rate  enhancements  and  minute  ventila-
ion rate  responsiveness  should  be  programmed  to  ‘‘off’’
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ode,  and  ICD’s  anti-tachyarrhythmia  functions  should  be
uspended, if  present.  For  ICD  patients  who  depend  on  pac-
ng function  for  control  of  bradyarrhythmia,  these  functions
hould be  altered  by  programming.6
The  lower  rate  limit  can  be  increase  to  optimize  oxygen
elivery to  tissues  for  major  cases.1
A  determination  as  to  whether  EMI  is  likely  to  occur
r not.  Anesthetic  techniques  do  not  inﬂuence  CRMD  func-
ion. However,  anesthetic-induced  physiologic  changes  (i.e.,
ardiac rate,  rhythm,  or  ischemia)  in  the  patient  may
nduce unexpected  CRMD  responses  or  adversely  affect  the
RMD--patient interaction.6
Appropriate  reprogramming  is  the  safest  way  to  avoid
ntraoperative problems,  and  is  required  in  any  rate
esponsive device,  hypertrophic  obstructive/dilated  car-
iomyopathy, pediatric  patients,  pacemaker-dependent
atients, major  procedure  in  the  chest/abdomen,  special
rocedures (lithotripsy,  TURP,  hysteroscopy,  ECT,  scoline
se, MRI).1 Temporary  pacing  and  deﬁbrillation  equipment
hould be  immediately  available  before,  during,  and  after  a
rocedure.6
ntraoperative considerations
eneral  anesthesia  can  present  a  range  of  problems  for  the
aced patients,  although  it  rarely  does  so  due  to  contem-
orary anesthesia  techniques.  The  Task  Force  agrees  that
 patient’s  electrocardiogram  (ECG)  should  be  continuously
isplayed and  continuous  peripheral  pulse  monitoring  should
e  performed  for  all  CRMD  patients  receiving  general  or
egional anesthesia,  sedation,  or  monitored  anesthesia  care.
echanical systole  (which  depicts  paced  electrical  activ-
ty) is  best  evaluated  by  pulse  oximetry  plethysmography,
r arterial  pressure  waveform  display.1 The  presence  of
acemaker is  not  an  indication  for  insertion  of  pulmonary
rtery (PA)  or  central  venous  catheter  (CVC).57 Insertion
f the  guide  wire  or  CVC  is  potentially  arrhythmogenic5
nd  dislodgement  of  freshly  placed  transvenous  endocar-
ial electrode  can  occur.  Therefore  care  should  be  taken
nd multipurpose  PA  catheter  with  pacing  facilities  can  be
sed.58 Emergency  drugs  should  be  kept  ready,  including
emporary pacing  and  deﬁbrillation.
Anesthetic  induction  with  succinylcholine  can  cause
igniﬁcant muscle  fasciculations  leading  to  complete  inhi-
ition of  pacemakers  because  of  oversensing,  resulting
n cardiac  arrest  in  pacemaker-dependent  patients.59 The
uscle fasciculation  induced  by  succinylcholine  can  be
voided by  using  non-depolarizing  muscle  relaxant  or  defa-
iculating with  nondepolarizing  muscle  relaxant  before
iving succinylcholine.8 This  complication  can  also  be  pre-
ented by  temporary  reprogramming  of  the  pacemaker  to
n asynchronous  mode.4 Narcotics  and  inhalational  tech-
iques do  not  alter  current  and  voltage  thresholds  of  the
acemaker,60 and  hence  can  be  used  safely.  Use  of  N2O
an cause  pacemaker  malfunction  by  increasing  gas  in  pre
ectoral pacemaker  pocket  (loss  of  anodal  contact).61 Eto-
idate and  ketamine  should  be  avoided  as  these  cause
yoclonic movements.5 Positive  pressure  ventilation  can
ause dislodgement  of  pacemaker  leads;  therefore,  pace-
aker function  should  be  veriﬁed,  before  and  after  initiating
echanical ventilation.62A.G.  Rapsang,  P.  Bhattacharyya
Many  metabolic  and  electrolyte  abnormalities  can  affect
acemaker function  and  therefore,  monitoring  for  such
vents is  essential.  Shivering  should  be  avoided  and  tem-
erature must  be  kept  constant  in  ‘temperature’  rate
esponsive pacemakers.9
If  unanticipated  device  interactions  are  found,  con-
ider discontinuation  of  the  procedure  until  the  source  of
nterference can  be  eliminated  or  managed.6 If  a  tempo-
ary pacemaker  fails  intraoperatively,  the  inspired  oxygen
oncentration should  be  increased  to  100%.  All  connections
nd the  generator  battery  should  be  checked.  The  gener-
tor should  be  set  into  the  asynchronous  mode,  and  the
entricular output  should  be  set  on  maximum.  Pharmacolog-
cal management  (atropine,  isoproterenol,  or  epinephrine)
ay be  useful  until  the  problem  is  resolved.  Failure  of
 temporary  transvenous  electrode  to  capture  the  ventri-
le is  usually  due  to  displacement  of  the  electrode  away
rom the  ventricular  endocardium;  careful  slow  advance-
ent of  the  catheter  or  wire  while  pacing  often  results
n capture.  If  an  adequate  arterial  blood  pressure  cannot
e maintained  with  adrenergic  agonists,  cardiopulmonary
esuscitation should  be  instituted  until  another  pacing  elec-
rode is  placed  or  a  new  generator  box  is  obtained.1 For  the
atient with  an  implanted  deﬁbrillator,  facilities  for  exter-
al deﬁbrillation  should  be  available  immediately  after  the
evice is  disabled.30 If  patient  develops  VT,  surgeons  should
e advised  to  terminate  all  sources  of  EMI,  magnet  should
e removed  to  enable  anti  tachycardia  activities,  device
hould be  observed  and  if  failed,  and  then  external  deﬁbril-
ation/cardioversion should  be  initiated.
Electrical  interference  from  surgical  electrocautery
nits, electroconvulsive  therapy,  lithotripsy  has  already
een discussed.
ost-operative considerations
onitor  cardiac  rate  and  rhythm  continuously  throughout
he immediate  postoperative  period.6
Emergency  drugs  and  equipments  should  be  kept  ready.6
The  device  should  be  reprogrammed  to  appropriate
ettings. For  an  ICD,  all  antitachyarrhythmic  therapies
hould be  restored.  Consultation  with  a  cardiologist  or
acemaker--ICD service  may  be  necessary.6
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